Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Chung-Liang Li"'
Autor:
Jung-Yu Kan, Shen-Liang Shih, Sheau-Fang Yang, Pei-Yi Chu, Fang-Ming Chen, Chung-Liang Li, Yi-Chia Wu, Yao-Tsung Yeh, Ming-Feng Hou, Chih-Po Chiang
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 2, p 1295 (2024)
Exosomal microRNAs (miRNAs) are novel, non-invasive biomarkers for facilitating communication and diagnosing cancer. However, only a few studies have investigated their function and role in the clinical diagnosis of breast cancer. To address this gap
Externí odkaz:
https://doaj.org/article/f69556f6645e44f3b052daaea94a6e8e
Autor:
Chung‐Liang Li, Cheng‐Che Wu, Jung‐Yu Kan, Fang‐Ming Chen, Ming‐Feng Hou, Chieh‐Han Chuang, Hsin‐I Huang, Fu Ou‐Yang
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 38, Iss 3, Pp 277-282 (2022)
Abstract This study aimed to investigate the effectiveness of neoadjuvant chemotherapy in patients with breast cancer in different age groups and evaluate the impact of age group on survival outcome according to different treatment responses. Data we
Externí odkaz:
https://doaj.org/article/b92fcfd606ce4f9e93182749a3cc4056
Autor:
Chia‐Yu Kuo, Jung‐Yu Kan, Chieh‐Ni Kao, Fu Ou‐Yang, Cheng‐Che Wu, Jun‐ping Shiau, Chung‐Liang Li, Ming‐Feng Hou, Shu‐Hung Huang
Publikováno v:
Clinical Case Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
Abstract NPWT fulfill graft taking in complex breast wounds.
Externí odkaz:
https://doaj.org/article/ce2e54246ebf43b1a371ec064001303b
Autor:
Chung-Liang Li, Sin-Hua Moi, Huei-Shan Lin, Ming-Feng Hou, Fang-Ming Chen, Shen-Liang Shih, Jung-Yu Kan, Chieh-Ni Kao, Yi-Chia Wu, Li-Chun Kao, Ying-Hsuan Chen, Yi-Chen Lee, Chih-Po Chiang
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 18, p 10539 (2022)
Endocrine therapy (ET) of selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs) has been used as the gold standard treatment for hormone-receptor-positive (HR+) breast cance
Externí odkaz:
https://doaj.org/article/54a29acbbf204502b189a0196e014822
Publikováno v:
Case Reports in Oncological Medicine, Vol 2018 (2018)
Compartment syndrome may be acute or chronic based on the clinical course and etiology. Here, we report the first known case to be diagnosed with skeletal muscle-derived B-cell lymphoma presenting with chronic compartment syndrome after trauma. A 62-
Externí odkaz:
https://doaj.org/article/f7b43b21b8044dcfa8b7dcd97d333efd
Autor:
Jui-Hung Tsai, Chung-Liang Li, Dah-Cherng Yeh, Chin-Sheng Hung, Chih-Chiang Hung, Chin-Yao Lin, Yao-Lung Kuo
Publikováno v:
Breast Cancer Research and Treatment. 199:47-55
Autor:
Fu Ou-Yang, Fang-Ming Chen, Jung-Yu Kan, Chieh-Han Chuang, Ming-Feng Hou, Cheng-Che Wu, Hsin-I Huang, Chung-Liang Li
Publikováno v:
The Kaohsiung Journal of Medical Sciences. 38:277-282
This study aimed to investigate the effectiveness of neoadjuvant chemotherapy in patients with breast cancer in different age groups and evaluate the impact of age group on survival outcome according to different treatment responses. Data were retros
Autor:
Chih-Po Chiang, Li-Chun Kao, Fu Ou-Yang, Chieh-Ni Kao, Chieh-Han Chuang, Fang-Ming Chen, Jung-Yu Kan, Yao-Tsung Yeh, Chung-Liang Li, Ming-Feng Hou, Yi-Chen Lee, Cheng-Che Wu, Jun-Ping Shiau, Chien-Ju Cheng, Shen-Liang Shih, Sin-Hua Moi
Publikováno v:
Experimental & Molecular Medicine
In Western countries, breast cancer tends to occur in older postmenopausal women. However, in Asian countries, the proportion of younger premenopausal breast cancer patients is increasing. Increasing evidence suggests that the gut microbiota plays a
Autor:
Fu Ou-Yang, Mei-Ren Pan, Chi-Wen Luo, Shao-Yu Fang, Chin-Ju Ko, Chia-Wei Huang, Ming-Feng Hou, Chung-Liang Li
Publikováno v:
Anticancer Research. 40:5529-5538
Background/aim Triple-negative breast cancer (TNBC) is a unique subtype that lacks expression of several conventional biomarkers and has a higher incidence of lymph node invasion and distal metastasis among all breast cancers. Anoikis resistance is t
Autor:
Fu, Ou-Yang, Chung-Liang, Li, Chia-Chi, Chen, Yi-Chun, Shen, Sin-Hua, Moi, Chi-Wen, Luo, Wei-Ya, Xia, Ying-Nai, Wang, Heng-Huan, Lee, Lu-Hai, Wang, Shao-Chun, Wang, Mei-Ren, Pan, Ming-Feng, Hou, Mien-Chie, Hung
Publikováno v:
Am J Cancer Res
The atezolizumab (Tecentriq), a humanized antibody against human programmed death ligand 1 (PD-L1), combined with nab-paclitaxel was granted with accelerated approval to treat unresectable locally advanced or metastatic triple-negative breast cancer